Biotechnology
Biopharmaceutical
Pharmaceutical

Fate Therapeutics

1,192

$14.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.58 (+4.14%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell FATE and other stocks, options, ETFs, and crypto commission-free!

About FATE

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Read More Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

CEO
J. Scott Wolchko
Employees
104
Headquarters
San Diego, California
Founded
2007
Market Cap
1.11B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
716.04K
High Today
$14.88
Low Today
$14.01
Open Price
$14.26
Volume
618.25K
52 Week High
$22.82
52 Week Low
$11.00

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Cancer Prevention
Therapy
Technology
2013 IPO

FATE Earnings

-$0.40
-$0.34
-$0.28
-$0.22
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
-$0.38 per share
Actual
-$0.40 per share
Replay Earnings Call

You May Also Like

NSPR
CORT
AFK
BCS
APPS
OXLCM
EWJ
YVR
HT-D
IBDR
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy FATE

Market Price$14.70
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell FATE stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up